Alnylam Pharmaceuticals, Inc

The Associate Director, US HEOR, VESt, is a member of the Alnylam Medical Affairs team.. These activities will be performed in cross-functional collaboration with a range of partners throughout the organization, including the US Market Access, US Medical Affairs, Medical Outcomes Science Liaison (MOSL), Public Policy & Government Relations, and US Regulatory Affairs teams.. Develop and maintain peer and KOL relationships to ensure up-to-date awareness of innovative HEOR methods and appropriate application of these methods within the context of evidence generation efforts for the Alnylam TTR amyloidosis franchise. 5-8 years of demonstrated high-level proficiency in an in-house or consulting role in the area of HEOR/market access, with rare disease experience preferred. Understanding of and experience in pharmaceutical product development and/or commercialization, including (but not limited to) evidence generation and access strategy and product portfolio strategy; experience with the development of value-based agreements for market access is a plus

associate director

Overview
The Associate Director, US HEOR, VESt, is a member of the Alnylam Medical Affairs team. Reporting to the Senior Director, VESt, the Associate Director will effectively execute on scientific activities and provide timely support for efforts in the United States to secure access to therapies in the Alnylam transthyretin (TTR) amyloidosis franchise. These activities will be performed in cross-functional collaboration with a range of partners throughout the organization, including the US Market Access, US Medical Affairs, Medical Outcomes Science Liaison (MOSL), Public Policy & Government Relations, and US Regulatory Affairs teams. Specific responsibilities include conceptualization, planning, design, implementation, and communication of economic analyses and health outcomes studies, with a focus on obtaining and disseminating meaningful findings that resonate with payers and other relevant access stakeholders in the United States. In addition, the successful candidate will play a key role in generating and contextualizing critical economic and clinical evidence for inclusion in payer-facing materials, including Academy of Managed Care Pharmacy (AMCP) dossiers, MOSL slide decks, reactive sample medical policy documents, and other field tools (e.g., cost of care calculators). The successful candidate will be self-motivated and collaborative, have strong quantitative skills and (more generally) mathematical intuition, and exhibit a high degree of intellectual curiosity.
Key Responsibilities
* Partner with cross-functional colleagues to thoroughly understand key gaps in the data needed to support market access for the Alnylam TTR amyloidosis franchise in the United States
* Contribute to the development of evidence generation plans geared toward addressing key data gaps to ensure optimal access for the Alnylam TTR amyloidosis franchise in the United States
* Execute on evidence generation plans by conducting cost-effectiveness analyses, budget impact analyses, and other studies (e.g., comparative effectiveness research, systematic literature reviews) as needed to address key data gaps in support of market access efforts in the United States
* Lead cross-functional teams in developing content for US payer materials such as AMCP dossiers, MOSL slide decks, and reactive sample medical policy documents
* Serve as a resource to US Market Access and Commercial colleagues for consultation on pricing, positioning, and reimbursement prospects for TTR amyloidosis treatments, along with cross-portfolio optimization of access and development of value-based agreements for these treatments, as informed by in-depth understanding of payer and physician decision-making dynamics in the United States
* Develop and maintain peer and KOL relationships to ensure up-to-date awareness of innovative HEOR methods and appropriate application of these methods within the context of evidence generation efforts for the Alnylam TTR amyloidosis franchise
Qualifications
* Advanced degree in a scientific, quantitative, or healthcare-related discipline
* 5-8 years of demonstrated high-level proficiency in an in-house or consulting role in the area of HEOR/market access, with rare disease experience preferred
* In-depth understanding of payer evaluation processes and funding mechanisms for pharmaceuticals in the United States; experience specifically related to integrated delivery networks (IDNs) is a plus
* Understanding of and experience in pharmaceutical product development and/or commercialization, including (but not limited to) evidence generation and access strategy and product portfolio strategy; experience with the development of value-based agreements for market access is a plus
* Strategic mindset and keen intellectual curiosity
* Strong analytical, written and verbal communication skills, mathematical reasoning capabilities, and interpersonal skills
* Comfort managing multiple projects simultaneously and navigating shifting priorities in a rapidly changing environment
* Ability to execute projects and deliver quality work product in a timely manner within a fast-paced environment
* Willingness to travel (up to 20%)
About Alnylam
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.<br/><br/>#J-18808-Ljbffr

START NEW SEARCH